Browsing Tag
Cambridge
27 posts
Fulcrum Therapeutics agrees reverse merger with Slate Medicines and $270m dividend
Fulcrum's $270m dividend and 5% stub hand Slate a Nasdaq listing, but SLTE-1009's PACAP bet must beat CGRP incumbents to justify a $350m valuation.
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.
UK-backed CuspAI targets semiconductor and energy bottlenecks with $450m round
CuspAI has secured $450 million at a $2.6 billion valuation to connect artificial intelligence, laboratories and manufacturers, but commercial value depends on turning digital candidates into validated materials.
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Akamai stock surges 20% on $1.8bn AI cloud deal: What AKAM investors need to watch next
Wall Street wrote off Akamai as a fading CDN name. One $1.8B cloud deal and 40% Cloud Infrastructure growth just rewrote the entire AKAM thesis overnight.
JuliaHub targets industrial digital twins with $65m Series B and Dyad 3.0 launch
Hardware still moves slowly while software races ahead. JuliaHub’s Dyad 3.0 aims to close that gap with agentic industrial AI.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
British Land (LSE: BLND) to acquire Life Science REIT in £150m science property deal
British Land to acquire Life Science REIT for £150M in a strategic science real estate deal. Find out how this reshapes the UK innovation leasing market.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.